These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 17090194)

  • 1. Phyllodes tumor: a clinicopathologic and immunohistochemical study of 30 cases.
    Esposito NN; Mohan D; Brufsky A; Lin Y; Kapali M; Dabbs DJ
    Arch Pathol Lab Med; 2006 Oct; 130(10):1516-21. PubMed ID: 17090194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoreactivity of p53, Ki-67, and c-erbB-2 in phyllodes tumors of the breast in correlation with clinical and morphologic features.
    Shpitz B; Bomstein Y; Sternberg A; Klein E; Tiomkin V; Kaufman A; Groisman G; Bernheim J
    J Surg Oncol; 2002 Feb; 79(2):86-92. PubMed ID: 11815995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 and Ki-67 expression as prognostic factors in cystosarcoma phyllodes.
    Erhan Y; Zekioglu O; Ersoy O; Tugan D; Aydede H; Sakarya A; Kapkaç M; Ozdemir N; Ozbal O; Erhan Y
    Breast J; 2002; 8(1):38-44. PubMed ID: 11856160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgical treatment of phyllodes tumors of the breast: retrospective review of 172 cases.
    Chen WH; Cheng SP; Tzen CY; Yang TL; Jeng KS; Liu CL; Liu TP
    J Surg Oncol; 2005 Sep; 91(3):185-94. PubMed ID: 16118768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2005 Galloway Memorial Lecture: Breast phyllodes tumours--morphology and beyond.
    Tan PH
    Ann Acad Med Singap; 2005 Dec; 34(11):671-7. PubMed ID: 16453039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of p53 and MIB-1 expression with both the systemic recurrence and survival in cases of phyllodes tumors of the breast.
    Yonemori K; Hasegawa T; Shimizu C; Shibata T; Matsumoto K; Kouno T; Ando M; Katsumata N; Fujiwara Y
    Pathol Res Pract; 2006; 202(10):705-12. PubMed ID: 16889904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 and c-kit (CD117) protein expression as prognostic indicators in breast phyllodes tumors: a tissue microarray study.
    Tan PH; Jayabaskar T; Yip G; Tan Y; Hilmy M; Selvarajan S; Bay BH
    Mod Pathol; 2005 Dec; 18(12):1527-34. PubMed ID: 16258510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Outcomes After Surgical Treatment of Malignant/Borderline Phyllodes Tumors of the Breast.
    Spanheimer PM; Murray MP; Zabor EC; Stempel M; Morrow M; Van Zee KJ; Barrio AV
    Ann Surg Oncol; 2019 Jul; 26(7):2136-2143. PubMed ID: 30783853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of EMP1, EMP2, and EMP3 in breast phyllodes tumors.
    Cha YJ; Koo JS
    PLoS One; 2020; 15(8):e0238466. PubMed ID: 32857809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of P53, Ki-67 expression in the differential diagnosis of benign/malignant phyllodes tumors of the breast.
    Kucuk U; Bayol U; Pala EE; Cumurcu S
    Indian J Pathol Microbiol; 2013; 56(2):129-34. PubMed ID: 24056649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinicopathologic features and prognostic factors of malignant phyllodes tumors].
    Jia C; Mei F; Zheng J; You JF; Liu JY
    Zhonghua Bing Li Xue Za Zhi; 2013 Nov; 42(11):729-34. PubMed ID: 24447548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An approach to malignant mammary phyllodes tumors detection.
    Ilić I; Randelović P; Ilić R; Katić V; Milentijević M; Velicković L; Krstić M
    Vojnosanit Pregl; 2009 Apr; 66(4):277-82. PubMed ID: 19441158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD34, CD117, and Ki-67 expression in phyllodes tumor of the breast: an immunohistochemical study of 33 cases.
    Noronha Y; Raza A; Hutchins B; Chase D; Garberoglio C; Chu P; Weiss L; Wang J
    Int J Surg Pathol; 2011 Apr; 19(2):152-8. PubMed ID: 21087983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of Local Recurrence of Benign and Borderline Phyllodes Tumors: A Danish Population-Based Retrospective Study.
    Borhani-Khomani K; Talman ML; Kroman N; Tvedskov TF
    Ann Surg Oncol; 2016 May; 23(5):1543-8. PubMed ID: 26714948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stromal cells in phyllodes tumors of the breast are enriched for EZH2 and stem cell marker expression.
    Zhang Y; Liss AL; Chung E; Pierce LJ; Kleer CG
    Breast Cancer Res Treat; 2016 Jul; 158(1):21-28. PubMed ID: 27290698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive factors of local recurrence and survival following primary surgical treatment of phyllodes tumors of the breast.
    Abdalla HM; Sakr MA
    J Egypt Natl Canc Inst; 2006 Jun; 18(2):125-33. PubMed ID: 17496937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of c-kit in fibroepithelial lesions of the breast is a mast cell phenomenon.
    Djordjevic B; Hanna WM
    Mod Pathol; 2008 Oct; 21(10):1238-45. PubMed ID: 18500266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased p53 protein expression in malignant mammary phyllodes tumors.
    Tse GM; Putti TC; Kung FY; Scolyer RA; Law BK; Lau TS; Lee CS
    Mod Pathol; 2002 Jul; 15(7):734-40. PubMed ID: 12118111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IMP3 Is Strongly Expressed in Malignant Phyllodes Tumors of the Breast: An Immunohistochemical Study.
    Bellezza G; Prosperi E; Del Sordo R; Colella R; Rulli A; Sidoni A
    Int J Surg Pathol; 2016 Feb; 24(1):37-42. PubMed ID: 26353850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histologic features predict local recurrence after breast conserving therapy of phyllodes tumors.
    Barth RJ
    Breast Cancer Res Treat; 1999 Oct; 57(3):291-5. PubMed ID: 10617306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.